Propafenone in complex anti-recurrent therapy of persistent atrial fibrillation
Abstract
Effectiveness and safety of Class IС antiarrhythmic agent, propafenone (Propanorm, PRO. MED. CS Praha a.s., Czech Republic), was studied inpatients with persistent atrial fibrillation (PAF) after sinus rhythm conversion, during long-term ant-recurrent treatment. The study included 30 men and women; mean age 57, 97± 1, 2 years. PAF was caused by essential arterial hypertension, or its combination with stable coronary heart disease. To treat PAF paroxysms, propanorm was administered in the loading dose of 600 mg, continued by anti-recurrent therapy (450 mg/d for 12 months). All participants also received ACE inhibitor lisinopril (Dapril, PRO. MED. CS Praha a.s., Czech Republic). During anti-recurrent propanorm therapy (450 mg/d), no recurrent AF paroxysms were registered in 63, 3 % of the patients; paroxysm frequency reduced in 23, 3 %; paroxysms remained frequent in 13, 3 %. No adverse events were registered. Twelve-month propanorm and dapril treatment was associated with significant improvements in intracardiac hemodynamics and chronic heart failure functional class, as early as by Month 6. |
About the Authors
V. V. Skibitsky
Кубанский государственный медицинский университет
Russian Federation
Russian Federation
E. A. Kudryashov
Кубанский государственный медицинский университет
Russian Federation
Russian Federation
A. V. Fendrikova
Краснодарский городской центр скорой медицинской помощи
Russian Federation
Russian Federation
N. A. Spiropulos
Краснодарский городской центр скорой медицинской помощи
Russian Federation
Russian Federation
З. Сокаева
Краснодарский городской центр скорой медицинской помощи
Russian Federation
Russian Federation
С. Прасолова
Краснодарский городской центр скорой медицинской помощи
Russian Federation
Russian Federation
Е. Городецкая
Краснодарский городской центр скорой медицинской помощи
Russian Federation
Russian Federation
References
1. Кушаковский М.С. Фибрилляция предсердий (причины, механизмы, клинические формы, лечение и профилактика). СПб.: ИКФ Фолиант, 1999. 176 с.
2. Боровков Н.Н. и др. Эффективность пропафенона в купировании пароксизмов фибрилляции предсердий//Российск. кард. ж. 2003. № 5. С. 65-67.
3. Яковлева Н.В., Заграй Н.А., Соболева В.А., Голицын С.П. Эффективность и переносимость пропафенона и хинидина у больных с пароксизмальной мерцательной аритмией//Кардиология. 1996. № 4. С. 37-41.
4. Антонченко И.В., Савенкова Г.М., Попов С.В. и др. Тактика фармакотерапии пароксизмальной формы фибрилляции предсердий//Progress in Biomedical Research. 1999; 4: 1: 65-69.
5. Atrial fibrillation: mechanisms and therapeutic strategies/ed., S.B. Olsson, M.A. Alessie et al. Futura Publishing сотр., 1994. 414 с.
6. Borggefe M., Candinas R., Nief С., et al. Effect of atrial fibrillation on inducibility of VT/VF during programmed ventricular stimulation//Circulation. 1991. Vol. 84. (Abstr.) P. II. P. 412.
7. Botto G.L., Capucci A., Bonini W. Conversion of recent onset atrial fibrillation to sinus rhythm using a single loading oral dose of propafenone. Comparison of two regiments//Int. J. Cardiol. 1997; 58: 55-61.
8. Chiang C.W., Lo S.K., Kuo S.T. et al. Noninvasive predictors of systemic embolism in mitral stenosis//Chest. 1994. Vol. 106. P. 396-409.
9. Ergene V., Ergene O., Fowler J. et al. Predictors of success in the conversion of new-onset atrial fibrillation using oral propafenone//Eur. J. Emerg. Med. 1998; 5: 425-8.
10. Диагностика и лечение фибрилляции предсердий. Российские рекомендации, 2005.
Review
For citations:
Skibitsky V.V., Kudryashov E.A., Fendrikova A.V., Spiropulos N.A., , , Propafenone in complex anti-recurrent therapy of persistent atrial fibrillation. Russian Journal of Cardiology. 2007;(4):44-47. (In Russ.)
Views:
468
Email this article 